The Children's Cancer Group (CCG) conducted three Phase III prospective clinical trials for children with de novo acute myeloid leukemia between the years 1979 and 1995. A total of 1903 eligible children ages birth to 21 years of age were enrolled on CCG 251 (n ¼ 485), CCG 213 (n ¼ 532) and CCG 2891 (n ¼ 886). Follow-up is ongoing, with medians of 7.9, 10.9 and 8.6 years, respectively. These three clinical trials developed dose-and time-intensive induction regimens based upon highdose cytarabine and daunomycin and randomly assigned patients to allogeneic bone marrow transplantation in first remission if an HLA-matched related donor was identified. Despite dose-and time-intensive induction regimens, remission induction rates remained relatively stable at 77-78%. However, overall survival, event-free survival and disease-free survival (DFS) increased for patients receiving intensive-timing induction therapy in comparison to patients who received standard-timing induction, regardless of the type of postremission therapy. Outcomes were best for patients receiving intensive-timing induction followed by matched related donor allogeneic transplantation with DFS of 6579% at 6 years. These three clinical trials have established a strong foundation for the development of future studies focusing on further risk group stratification and the development of novel, molecularlytargeted therapies.
Introduction
The Children's Cancer Group (CCG) was the first cooperative cancer group founded by the National Institutes of Health's (NIH) National Cancer Institute (NCI). The CCG (originally called the Children's Cancer Study Group (CCSG)) was founded in 1955 as the Acute Leukemia Chemotherapy Cooperative Study Group A (ALCCSGA). The first randomized, Phase III study in childhood cancer was conducted by the ALCCSGA for children with acute leukemia. Between 1955 and 1957, nine participating institutions enrolled 168 children with acute leukemia on a trial of 6-mercaptopurine (6-MP) vs 6-MP plus azaserine.
In its final year (1999), the CCG consisted of 238 institutions in the United States, Canada and Australia. The estimated annual number of children with newly diagnosed de novo acute myeloid leukemia (AML) cared for in CCG institutions was approximately 250 per year. Over the last 31 years of its history, the CCG conducted six randomized, Phase III studies in children with AML (CCG 102, CCG 241, CCG 251, CCG 213, CCG 2891, CCG 2961). In the years encompassing this report (from 1979 to 1995) , the CCG performed three, Phase III randomized clinical research trials for children with de novo AML: CCG 251, CCG 213 and CCG 2891. The CCG completed its last Phase III AML trial (CCG 2961) in 2003. Subsequent AML Phase III studies have been developed and executed within the Children's Oncology Group (COG). [1] [2] [3] The COG was established in 2000 as an NCI-supported cooperative pediatric cancer group that resulted from the merger of the CCG, the Pediatric Oncology Group, The National Wilm's Tumor Study Group and the Intergroup Rhabdomyosarcoma Study Group. COG institutions capture virtually all children with cancer in the United States, Canada, Australia, New Zealand and Switzerland.
The foundation for the 'modern era' of AML therapy was laid in the 1970s. During the years between 1972 and 1979, the CCSG conducted three studies of the treatment of children with de novo AML. The first of these clinical trials, CCG 102, was conducted between 1972 and 1975. It consisted of four to seven 14-day courses of a five-drug regimen consisting of vincristine, prednisolone, cytosine arabinoside (cytarabine), 6-thioguanine (6-TG) and cyclophosphamide (PATCO). 4 Maintenance therapy consisted of 3-5 years of continuous daily 6-TG, one dose of vincristine and 4 days of cytarabine and cyclophosphamide administered in 28-day cycles. No central nervous system (CNS) therapy was directed by the protocol and bone marrow transplantation (BMT) was not utilized. The maintenance treatment duration was 3-5 years.
The successor study to CCG 102, CCG 241 was conducted in two parts between 1975 and 1979. 5 CCG 241 induction (1975) (1976) (1977) included four to seven courses of chemotherapy consisting of 14-day cycles of vincristine, prednisolone, cytarabine, 5-azacytidine (5-Aza) and daunomycin (D-ZAPO). Maintenance chemotherapy was similar to that of CCG 102 except for the substitution of 5-Aza for cyclophosphamide and 6-TG was administered only on days 1-10 rather than continuously. During the first three maintenance courses, patients were randomized to receive (or not receive) immunotherapy with Bacillus Calmette-Guerin (BCG), with the coadministration of allogeneic myelomonocytic leukemia cells. After six months of maintenance chemotherapy, patients received 2400 cGy of cranial radiation and six weekly doses of intrathecal methotrexate. The duration of maintenance treatment was four years. Bone marrow transplantation was not utilized in the study. The CCG 241A study (1977) (1978) (1979) modified the CCG 241 maintenance to eliminate the immunotherapy component, and returned to the use of cyclophosphamide and 6-TG.
Relapse-free survival (RFS) rates at 6 years for CCG 102, CCG 241 and CCG 241A were 14, 11 and 19%, respectively. 6 As will be discussed in this manuscript, disease-free survival (DFS) would be improved in the next two decades by the introduction of dose and time-intensive induction chemotherapy using cytarabine and anthracyclines, the addition of matched related donor BMT while in first complete remission (CR1) and the elimination of cranial radiation and maintenance chemotherapy.
In the years 1979 and 1995, the CCG conducted three prospective, randomized Phase III clinical trials (CCG 251 consisting of two parts, CCG 251A and CCG 251D, CCG 213 and CCG 2891). Table 1 summarizes the study period for each trial, the total number of de novo AML patients (age p21 years) enrolled on each study, the number of participating institutions, median number of patients enrolled per institution, total annual accrual and median follow-up. 14-day cycles of cytarabine 100 mg/m 2 administered intravenously as a continuous infusion for 7 days and doxorubicin (Adriamycin) 30 mg/m 2 intravenous (i.v.) for 3 days ('7 þ 3'). Therapy was reduced to 5 days of cytarabine and 2 days of doxorubicin after course 1 for patients with significant marrow hypocellularity and o15% blasts. 7 After induction, patients with an HLA-matched sibling donor underwent allogeneic BMT in CR1 after a preparative regimen of cyclophosphamide (60 mg/kg intravenously for 2 days) and single dose total body irradiation (TBI) (1000 cGy at 10 cGy/min dose rate) with 'long-course' methotrexate (15 mg/m 2 intravenously on day 1, 10 mg/m 2 on days 3, 6, 11, 18 and weekly until day 100) for graft-versus-host disease (GVHD) prophylaxis. Patients without a matched sibling donor received 1800 cGy cranial radiation and three weekly courses of 6-TG (60 mg/m 2 orally, days 1-4), cytarabine (50 mg/ m 2 subcutaneously on day 5) and intrathecal methotrexate. Nontransplant patients were randomized to continuous maintenance like CCG 241A (5-Aza, cytarabine, carmustine (BCNU), 6-mercaptopurine (6-MP), methotrexate, prednisone, vincristine and 6-TG) or 5-drug cyclic maintenance (5-Aza, cytarabine, cyclophosphamide, vincristine and 6-TG). The first 4 courses of cyclic maintenance were 21-28 days in duration and were given once per cycle. The fifth course was 7 days in duration and was given three times per cycle. Each cycle was 112 days in length for a total duration of 2 years of maintenance chemotherapy. Four courses of intrathecal methotrexate were administered. CCG 251D: In November 1980, all doses of chemotherapy for children less than 3 years were changed to use kilogrambased dosing rather than meter-squared dosing. As a result of severe mucositis and gastrointestinal toxicities, daunomycin replaced Adriamycin in all phases of the study. All other aspects of the study were the same as CCG 251A. Following remission induction with one or more courses of induction therapy, patients with an HLA-matched sibling or related donor or a related donor with a one-antigen mismatch at the HLA-A or HLA-B loci underwent bone marrow transplantation. The preparative regimen consisted of fractionated TBI (1200 cGy delivered as 200 cGy twice daily on days À5, À4 and À3) followed by cyclophosphamide (60 mg/kg on days À2 and À1). GVHD prophylaxis consisted of 'short course' methotrexate (15 mg/m 2 on day 1, 10 mg/m 2 on days 3, 6 and 11) and cyclosporine.
Patients and methods

Eligibility
Patients without a matched related donor received consolidation therapy. The first course of consolidation consisted of two cycles of high-dose cytarabine (3.0 g/m 2 i.v. every 12 h for four doses) and L-asparaginase (6000 units/m 2 at hour 42) with the second cycle started 7 days after the beginning of the first cycle (Capizzi II). The second course of consolidation consisted of PATCO as administered as maintenance therapy for CCG 251 and CCG 241. The third course of consolidation consisted of one cycle of DENVER chemotherapy with a single dose of daunorubicin as the only modification. Following consolidation, patients were randomized to receive 18 months of PATCO as maintenance therapy or no further therapy.
CNS prophylaxis consisted of intrathecal cytarabine on the first day of each cycle of induction therapy and for those patients not undergoing allogeneic BMT, throughout the consolidation phase, with the exception of the high-dose cytarabine course. Treatment of CNS disease consisted of intrathecal cytarabine weekly throughout induction and monthly throughout consolidation. Cranial radiation was used only if blast cells were not cleared with intrathecal cytarabine.
CCG 2891: Induction therapy consisted of a 5-drug cycle of chemotherapy that was administered over a 4-day period. . Patients randomized to standard timing of these agents had a bone marrow examination on day 14. Patients without evidence of leukemia at day 14 (M1 bone marrow) had the second cycle of DCTER delivered after recovery of blood counts. Patients with evidence of persistent leukemia had the second cycle of chemotherapy administered on day 14. Patients randomized to intensive timing had the second cycle of DCTER after a 6-day rest irrespective of blood counts and bone marrow status. Based upon interim analysis demonstrating superior results with intensively timed induction therapy, the standard timing arm was closed. In 1993, the study was further amended to include the use of granulocyte-colony stimulating factor (G-CSF) with intensively timed induction therapy.
Patients with a five-or six-antigen HLA matched, mixed leukocyte culture (MLC) compatible family donor were allocated to allogeneic BMT. All other patients were randomized to autologous bone marrow harvest with 4-hydroxycyclophosphamide (4-HC) ex vivo purging 11, 12 or intensive chemotherapy.
Patients undergoing allogeneic or autologous bone marrow transplantation received a preparative regimen of busulfan 1 mg/kg/dose orally every 6 h for 16 doses on days À9 to À6 with cyclophosphamide 50 mg/kg/day i.v. daily on days À5 to À1. For patients undergoing allogeneic BMT, 'long-course' methotrexate was used for GVHD prophylaxis.
For patients randomized to receive non-BMT intensive postremission therapy, four total courses of three different chemotherapy regimens were utilized. Course 1 consisted of Capizzi II high-dose cytarabine and L-asparaginase. Following hematologic recovery, patients received a second and third course of therapy consisting of two 28-day cycles of PATCO as previously described above. The fourth course consisted of DENVER chemotherapy as previously described above.
Following diagnostic lumbar punctures at diagnosis, all patients received four doses of intrathecal cytarabine at the start of each DCTER cycle. For patients with CNS meningeal leukemia, intrathecal cytarabine was administered twice a week for a total of six doses. Kaplan-Meier method was used to calculate estimates of overall survival (OS), event-free survival (EFS) and DFS. 13 OS was defined as the time from study entry to death from any cause. EFS was defined as the time from study entry to remission failure after two courses of therapy, marrow relapse, CNS relapse or death. DFS was defined as the time from achieving remission at the end of two courses of therapy to marrow relapse, CNS relapse or death from any cause. Patients lost to follow-up were censored at their date of last known contact or at a cutoff of August 2002, February 2001 and July 2003 for CCG 251, CCG 213 and CCG 2891, respectively. Confidence intervals (CI) were calculated using Greenwood's standard errors for OS, EFS and DFS estimates.
Definitions and statistics
14 Differences in OS, EFS and DFS were tested for significance using the log-rank statistic. The significance of observed differences in proportions was tested using the w 2 test and Fisher's exact test when data were sparse. The MannWhitney test was used to determine the significance between differences in medians. 15 Patients defined as favorable risk were those having a cytogenetic classification of t(8;21), inv (16) or t(15;17); patients having cytogenetic data available were defined as normal or other risk.
CR for CCG 251 and CCG 213 was defined as a hypocellular bone marrow with 1 þ cellularity with o5% blasts, recovery of peripheral blood counts with an absolute neutrophil count 4750 per mm 3 within one week of marrow results, platelet count 475 000 per mm 3 and no evidence of extramedullary disease. CR for CCG 2891 was defined as a bone marrow with p5% blasts on a marrow biopsy exhibiting moderate hypocellularity in addition to peripheral blood counts indicating recovering marrow function as defined by an absolute neutrophil count 41000/mm 3 and platelet count 4100 000/mm 3 obtained within 1 week of bone marrow results.
Results
Prior study results
In the studies conducted in the years between 1972 and 1979, CCG 102 and CCG 241 and CCG 241A demonstrated improving remission induction rates of 48, 54 and 65%, respectively, with 4-year survival rates from the time of study entry of 19, 15 and 27%. 6 Induction mortality remained high at 20, 19 and 19% with induction failure evident in 22, 8 and 5%, respectively. Remission induction success was not related to patient sex or morphologic type, but was associated with initial WBC (decreased induction success with increasing WBC) and age (decreased induction success with increasing age). RFS at 6 years increased only modestly over the course of these studies, increasing from 14% in CCG 102 to 19% in CCG 241A. These results serve as the baseline for the clinical trials discussed in this report.
Overall outcomes for CCG 251, 213 and 2891
As illustrated in Table 1 , a total of 1903 patients were enrolled on three consecutive CCG Phase III, randomized, prospective clinical trials for de novo AML in the years between 1979 and 1995. Demographic, clinical, laboratory and cytogenetic characteristics of patients are shown in Table 2 . The number of patients in each age group remained relatively constant throughout the study period with 14-22% of enrolled patients less than 2 years of age at diagnosis, 39-43% of patients 2-10 years, and 37-43% of patients greater than 10 years of age. The WBC at diagnosis was similar with 48-56% of patients having a WBC o20 000/mm 3 and 11-17% of patients having a WBC 4100 000/mm 3 . The incidence of CNS leukemia was infrequent, with only 6-9% having CNS disease at diagnosis.
All FAB subclasses were represented in CCG 2891. However, the FAB M0 subclass was not yet defined for CCG 251 and CCG 213. Patients with FAB M3 morphology (acute promyelocytic leukemia) were enrolled on all three studies, but were excluded from CCG 2891 in 1992 when the Intergroup APL study INT 0129 (CCG 2911) opened. Finally, the FAB M7 (megakaryoblastic leukemia) subclass was not yet defined for the CCG 251 study. With these exceptions, the incidence of FAB subclasses was similar across studies.
The percentage of patients with favorable cytogenetics (inv(16), t(8;21) and t(15;17)) was similar, ranging from 13 to 28%. The t(8;21) group was the most common, 8-13% of patients with t(15;17) 4-10% and inv(16) in 2-7%.
For all eligible patients on CCG 251, 213 and 2891, the probability of remission induction remained constant at 77, 78 and 77%, respectively. However, in CCG 2891, patients receiving standard timing induction had an induction remission rate of 72% while patients receiving intensive timing induction had an induction remission rate of 80% (P ¼ 0.011). The probability of induction failure (eg, primary refractory disease) was 12, 16 and 18% for CCG 251, CCG 213 and CCG 2891, respectively. For patients receiving standard timing DCTER induction on CCG 2891, the induction failure rate was 24%, but only 11% for patients receiving intensive timing DCTER induction. Deaths during induction were 12%, 5% and 5% for CCG 251, CCG 213 and CCG 2891, respectively. The percentage of patients undergoing HLA-matched related donor allogeneic bone marrow transplantation in CR1 remained stable across studies at 22, 22 and 25%, respectively.
Outcomes for all patients are illustrated in Table 3 and Figures  1 and 2 , with outcomes for patients less than 15 years shown in Table 4b . OS at 10 years improved over the course of these trials, improving from 3175% on CCG 251, to 3574% on CCG 213, to 4373% on CCG 2891. EFS and DFS at 10 years showed a similar improvement over the study period, increasing from 2974 and 3675%, respectively, on CCG 251 to 3273 and 4474%, respectively, for CCG 2891. EFS and DFS was highest for patients on CCG 2891 receiving intensive timing DCTER, with actuarial survival at 10 years of 3974 and 5175, respectively. Finally, the probability of death while in CR did not change over the course of these studies, with probabilities of nonrelapse mortality of 15% on CCG 251, 16% on CCG 213 and 15% on CCG 2891. The probability of death at various stages of therapy (eg, early death before the initiation of therapy, death within 15 days of study entry and death between days 15 and 150 while on therapy) are shown in Table 5 .
The greatest improvement in OS, EFS and DFS and decrease in the probability of relapse occurred in patients receiving intensive timed DCTER induction as administered on CCG 2891. Outcomes were superior for these patients, regardless of the postremission therapy administered as chemotherapy, autologous bone marrow transplantation or allogeneic bone marrow transplantation.
9,10,16
Related donor bone marrow transplantation
In CCG 251, children who achieved remission were randomly assigned to HLA-matched sibling bone marrow transplantation if a donor was identified. 7, 17 A preparative regimen of single dose TBI and cyclophosphamide with long-course methotrexate as GVHD prophylaxis was utilized. Out of 371 patients entering remission, 89 children had a donor identified. Children identified as having a matched related donor had a superior survival at 8 years in comparison to patients without a donor (47 vs 34%, Pp0.05).
In CCG 213, TBI was fractionated and GVHD prophylaxis consisted of short-course methotrexate and cyclosporine. 8, 18 Of 396 patients who entered remission, an HLA-matched family Nonresponse: patients who did not achieve remission and who survived 442 days from study entry. Death in CCR: patients in continuous complete remission (CCR) with a nonprogressive disease-related death. a Percentages of those evaluable for response.
Figure 1
Overall survival for CCG 251, CCG 213 and CCG 2891, standard and intensive timed induction.
Figure 2
Event-free survival for CCG 251, CCG 213 and CCG 2891, standard and intensive timed induction. member was identified in 113 patients. In intent-to-treat analyses, OS and DFS at 5 years showed a trend to improved outcome for patients identified as having a matched related donor when compared to patients without a donor (OS: 52 vs 46%, P ¼ 0.13; DFS: 46 vs 38%, P ¼ 0.06).
In CCG 2891, oral busulfan replaced TBI in the preparative regimen and long-course methotrexate was again used for GVHD prophylaxis. 10, 19 Of 653 patients who entered remission, a matched related donor was identified for 181 patients. DFS at 6 years was superior in allogeneic transplant recipients in comparison to recipients of autologous bone marrow transplants and chemotherapy, with DFS in 67 and 42% for allogeneic transplant patients who received intensive and standard timing induction, respectively. 19 
Prognostic factors
Prognostic factors for CCG 251 16, 20, 21 and CCG 213 [22] [23] [24] [25] have been previously published. The prognostic value of demographic, clinical and laboratory variables for patients enrolled on CCG 2891 is currently under analysis.
For CCG 251, younger age (less than 1 year) at diagnosis, increasingly high WBC at diagnosis 6 and high cell surface expression of CD33 antigen 20 predicted a worse outcome while monosomy 7 cytogenetic abnormalities resulted in a lower probability of the successful induction of remission. 21 In CCG 213, multivariate analyses suggested that a high platelet count at diagnosis (420 000/mm 3 ), absence of hepatomegaly, p15% day 14 bone marrow blasts percentage and abnormal chromosome 16 were independently associated with better induction success and survival. 22 Other prognostic value studies for CCG 213 demonstrated no prognostic value for the cell surface expression of lymphoid antigens by AML blasts 23 or cell surface expression of c-Kit. 24 Interesting, the cell surface expression of the human homologue of the rat NG2 chondroitin sulfate proteoglycan was associated with MLL gene rearrangements with abnormalities of chromosome band 11q23 and predicted a worse outcome. Table 6 summarizes the EFS for patients on CCG 251, CCG 213 and CCG 2891 according to risk group, cytogenetic features, FAB classification, response to induction based upon the percentage blasts on day 15 of induction, age and CNS involvement. For CCG 251 patients having cytogenetic data available for review, patients were defined as standard risk (SR) if they had favorable cytogenetics (inv(16), t(8;21) or t(15;17)) or FAB M3. Otherwise, patients were defined as high risk (HR). For CCG 213 and 2891 patients having cytogenetic data, patients were SR if they had favorable cytogenetics, FAB M3, FAB M1 (with Auer), FAB M2 (with Auer) or FAB M4eo. Otherwise, patients were HR. In the most recent study CCG 2891 that utilized the most intensive induction therapy, patients with favorable cytogenetics (inv(16), t(8;21) and t(15;17) had EFS at 5 years of 4177, 45713 and 31717%, respectively, compared to an EFS probability of 3076% for patients with normal cytogenetics and 30% for patients will all other cytogenetic abnormalities. Detailed analysis of the impact of FAB M0, M6 and M7 morphology for patients on CCG 2891 is in progress. As demonstrated in Table 6 , all three studies suggested a worse EFS for patients with WBC at diagnosis 4100 000/mm 3 and CNS disease at diagnosis. CCG 213 and 2891 suggested worse EFS for patients with 45% blasts on day 15 of induction. Finally, analysis of extramedullary disease for patients on CCG 251, CCG 213 and CCG 2891 identified nonskin, extramedullary disease as a favorable risk feature. 16 
Down's syndrome
Owing to concerns about excessive toxicity associated with chemotherapy in children with Down's syndrome and AML, few children were previously enrolled in cooperative group clinical trials. 26 However, due to improved understanding of approaches to the treatment of these children, the CCG was able to conduct the largest series to date (n ¼ 161) for the uniform treatment of children with Down's syndrome and AML. 27, 28 This prospective study demonstrated excessive toxicity with intensive timed DCTER induction therapy and allogeneic bone marrow transplantation for postremission therapy for children with Down's syndrome. For the 161 patients treated with four standard timed DCTER induction courses and Capizzi II chemotherapy in the postremission phase of therapy, outcomes were excellent, with remission induction rates of 91% and EFS of 77% at 8 years. Multivariate analyses demonstrated only age at diagnosis of 2 years or older as a risk factor for greater relapse risk (P ¼ 0.006) and worse survival. This large study demonstrated excellent outcomes with standard induction therapy, with a decline in survival with increasing age.
Discussion
Significant progress in improving the outcome of children with de novo AML was made over the course of these three CCG Phase III clinical trials. Several critical lessons were learned from these studies that have established the essential treatment platforms for contemporary clinical trials.
First, and perhaps most important, was the identification of high-dose cytarabine and anthracyclines as effective chemotherapeutic agents for childhood AML, with an increase in induction success and survival as these agents were introduced in the CCG 241 study 6 and in subsequent studies, knowledge was gained about optimally using these agents. The combination of cytarabine and daunomycin was not only carried forward in this series of AML studies, but the dose of delivered drug was increased as was the timing of delivery (eg, intensive timing). The impact of dose and time intensity is clearly evident in the CCG 2891 study where patient outcome is superior for patients receiving intensive timing induction, regardless of the therapy administered in the postremission phase of therapy. While not measurable in the context of this study, these results suggest that the 'depth' of remission induced during the induction period has a profound impact on ultimate survival, even a decade later. While CCG 213 and CCG 2891 added additional chemotherapy agents in increasing doses, the impact of these additional agents has not been critically assessed in prospective, randomized clinical trials. These three studies also addressed treatment strategies in the postremission phase of therapy. In contrast to CCG 102 and CCG 241 where therapy, including maintenance chemotherapy lasted for up to 5 years and for up to 2 years for CCG 251, the CCG 213 study showed that maintenance therapy was neither required and is potentially deleterious 8 in the setting of intensive treatment regimens. The data from these trials also support the benefit of matched related donor allogeneic bone marrow transplantation for children in a first clinical remission. The superior outcomes associated with transplantation were particularly evident for patients who received intensive timing induction chemotherapy. Autologous bone marrow transplantation, as performed in CCG 2891, was not found to be superior to chemotherapy. Finally, this series of CCG trials did not use cranial radiation as a component of therapy.
While definitive analyses of prognostic factors for patients on the CCG 2891 study are in progress, factors generally predictive of a worse outcome include increasing WBC at diagnosis, a poor response to therapy as measured by percentage blasts on day 15 of induction and monosomy 7. The prognostic impact of favorable cytogenetics for children receiving intensive timing induction is still under analysis. More recent efforts to identify factors that will allow for further risk group stratification of de novo AML include the identification of minimal residual disease by flow cytometry, 29 FLT3 internal tandem duplications [30] [31] [32] and expression microarray data. 33 New knowledge derived from these studies has helped establish the foundation for the next generation of COG clinical trials for children with de novo AML. The successor studies to CCG 2891, CCG 2961 1 and its pilot, CCG 2941 2 studied idarubicin-based intensive timing induction therapy and the use of interleukin-2 following Capizzi II intensification therapy. 3 Building upon these results, the overall therapeutic strategies of the COG are focusing on further risk group stratification and molecularly targeted agents for specific risk groups. 34 Examples include the continued development of all-trans retinoic acid (ATRA) and arsenic for APL, gemtuzumab ozogamicin for de novo and relapsed AML, imatinib for Philadelphia chromosome positive AML, FLT3 inhibitors and farnesyl transferase inhibitors for minimal residual disease following transplantation. Finally, the potential therapeutic benefit of the graft-versus-leukemia effect will be exploited in studies for children with very high-risk disease (eg, primary induction failure and monosomy 7 ).
